BAX

Healthcare company Baxter International (NYSE:BAX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 5% year on year to $2.98 billion. Its non-GAAP profit of $0.58 per share was 11.9% above analysts’ consensus estimates.

Baxter’s shares fell by over 4% on 29 October after adjusted earnings per share (EPS) dipped 16% year-over-year, despite positive revenue results.

Baxter International (NYSE:BAX) received an FDA warning letter citing multiple CGMP violations at a U.S. drug manufacturing site.

Baxter International (NYSE:BAX) raised its full-year 2026 outlook after reporting third-quarter sales and adjusted earnings that exceeded its expectations, citing broad-based growth across its portfolio, improving execution and strong free cash flow…

BAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.

Healthcare company Baxter International (NYSE:BAX) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 5% year on year to $2.98 billion. Its non-GAAP profit of $0.58 per share was 11.9% above analysts’ consensus estimates.

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Baxter (BAX) delivered earnings and revenue surprises of +13.73% and +2.48%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

(AP) — Baxter International Inc. (BAX) on Thursday reported third-quarter net income of $294 million, after reporting a loss in the same period a year earlier.